XML 58 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies (Details) (USD $)
0 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 24, 2013
Feb. 28, 2013
Feb. 28, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period           10 years    
Stock-based compensation           $ 167,000   $ 731,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options       1,600,000 600,000 1,600,000 600,000  
Unvested stock options, unrecognized compensation expense weighted average recognition period           3 years    
Stock options, granted       4,020,500 477,500 5,933,000 626,500  
Stock options, fair value assumptions, risk free interest rate       1.39% 0.70%      
Stock options, fair value assumptions, dividend yield       0.00% 0.00%      
Stock options, fair value assumptions, expected life       4 years 6 months 3 days 5 years      
Stock options, fair value assumptions, historical volatility rate       105.00% 114.00%      
Stock options, fair value assumptions, forfeiture rate       11.06% 3.88%      
Common stock rights issued 8,300,000 1,791,268 13,171,268 10,091,268        
Deferred revenue       1,147,000   1,147,000   1,171,000
Other accrued liabilities       2,393,000   2,393,000   3,686,000
Foreign currency translation adjustment, net of tax       104,000 88,000 (69,000) 98,000 99,000
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)           44,730,497 30,836,894  
CEO
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common stock rights issued       1,000,000        
CFO
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common stock rights issued       660,000        
Pharmacogenomic services
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Deferred revenue       200,000   200,000   200,000
Diagnostic tools
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Other accrued liabilities       900,000   900,000   1,000,000
Additional Paid-in Capital
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation               731,000
Additional Paid-in Capital | Selling, General and Administrative Expenses [Member]
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation           167,000 500,000  
Accumulated Other Comprehensive Income
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Foreign currency translation adjustment, net of tax           (69,000)   99,000
Minimum
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock options, unvested options, vesting period           1 year    
Maximum
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock options, unvested options, vesting period           3 years    
Accumulated Other Comprehensive Income | Maximum
               
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Foreign currency translation adjustment, net of tax           $ 50,000 $ 70,000